MedTrace Logo

Defining the Ablative Dose for Y-90 TARE

NCT07586046 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-05-14

No results posted yet for this study

Summary

This study is being done to help doctors improve how they treat liver tumors that cannot be removed by surgery or treated with standard ablation techniques. The researchers want to find out the best amount of radiation that needs to be delivered to completely destroy (or ablate) parts of the liver that have cancer.

Conditions

  • HCC - Hepatocellular Carcinoma

Interventions

OTHER

Yttrium-90 Radiation Segmentectomy (Y90 RS) using glass microspheres

The objective of this study is to define an optimal "ablative dose" range for Y90 Radiation Segmentectomy that achieves complete sectoral ablation detectable on dual contrast MRI and to determine whether this dose-response relationship differs between cirrhotic and non-cirrhotic patients.

Sponsors & Collaborators

  • Radiological Society of North America

    collaborator OTHER

  • Northwestern University Feinberg School of Medicine

    collaborator OTHER

  • Robert H. Lurie Cancer Center

    collaborator OTHER

  • Northwestern University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2029-02-28
Completion
2029-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07586046 on ClinicalTrials.gov